A pill to treat postpartum depression? It’s here

The fast-acting pill, paired with psychosocial treatment, offers a comprehensive treatment plan, but price concerns remain

5:00 AM

Author | Patricia DeLacey

woman sitting and using cell pill crib teddy bear blue pink
Justine Ross, Michigan Medicine

Listen to this article on Health Lab's podcast

The first oral medication to treat postpartum depression, zuranolone (branded Zurzuvae), received approval from the Food and Drug Administration in August 2023.

Taken orally once a day for 14 days, the pill starts relieving depressive symptoms after about three days and the effects last up to 45 days.

Zuranolone supplies a mimic of allopregnanolone – a neurohormone that decreases rapidly after pregnancy – that acts on receptors to reverse the withdrawal effects that impact mood.

This mechanism differs from most anti-depressants, which target neurotransmitters and take up to six to eight weeks to take effect.

The fast-acting pill offers more convenience than the postpartum depression infusion treatment, brexanolone (branded Zulresso), which has been available since 2019, but cost concerns remain.

As with all mental health medications, zuranolone should be paired with psychosocial treatment to treat all factors contributing to the disease.

SEE ALSO: A $34,000 Drug for Postpartum Depression Brings Praise, Price Concerns

“We get excited about new medicines – which are wonderful – but we put a lot of resources towards developing medicines when known psychosocial risks need our attention as well. These risks often get forgotten and stay unaddressed,” said Maria Muzik, M.D., M.Sc., a professor in the Michigan Medicine departments of psychiatry and obstetrics and gynecology.

A ‘multifactorial origin’

Like during depressive periods at any other time in life, postpartum depression is characterized by symptoms such as low energy, sad or irritable mood, sleeping/eating too much or too little, or not feeling joy in expected activities, including caring for the baby. In severe cases, postpartum depression can be life-threatening as mothers may experience thoughts of harming themselves or their child.

SEE ALSO: Insomnia and Postpartum Depression: When a New Mom’s Sleep Loss Turns Perilous

Both biological factors, like the shift in the hormonal landscape after birth, and psychosocial factors contribute to the development of postpartum depression, says Muzik.

“Because postpartum depression has a multifactorial origin, we also need multilevel treatments. In clinical practice, we first address psychosocial factors with a wide range of evidence-based psychotherapies and support and then address biological factors with medications,” said Muzik.

Treating postpartum depression

Psychoeducation should come first, says Muzik. Women often don’t realize they are depressed or downplay their symptoms.

“Many women feel guilty for their depressive symptoms, and we must educate them that their symptoms are part of a treatable illness. They are not weak.”

SEE ALSO: A Third of New Moms Had Postpartum Depression During Early Covid

Peer-to-peer support groups, where moms support other moms, are enormously helpful. Psychotherapy, like cognitive behavioral therapy, interpersonal therapy, or parent-infant psychotherapy can help women work through their anxious or depressive feelings and support their parenting confidence while also developing strategies to avert future flare ups.

Until now, the mainstay of biological treatment for postpartum depression were anti-depressants or anti-anxiety medications that increased serotonin levels in the brain called selective serotonin reuptake inhibitors or SSRIs.

The newly approved zuranalone will offer another, mechanistically totally different, option for treating the biological underpinnings of postpartum depression.

“Postpartum depression co-occurs with anxiety even more so than major depressive disorder,” said Muzik.

“Zuranolone works on allopregnanolone receptors to decrease anxiety, insomnia, and depression associated with postpartum depression.”

Side effects of the medication include dizziness and sedation which prohibits patients from driving or operating machinery while taking the medication.

Patients cannot take the medication while pregnant and cannot breastfeed while taking the medication and for a week afterwards.

Importantly, zuranolone has an addictive potential and should be avoided in individuals with a history of addiction.

Cost concerns

It is not yet clear whether zuranolone will remain as costly as its intravenous predecessor, brexanalone.

Currently, zuranolone is FDA approved only for the treatment of postpartum depression and not for major depressive disorder.

Sage Therapeutics, the drug manufacturer, originally projected the price for zuranolone to stay under $10,000 if it was also approved for major depressive disorder. Now that the market is smaller, the price will likely increase.

If it’s not fully subsidized by Medicare or insurance companies, this medication will heighten health care inequities, says Muzik.

Those who can afford the medication or have insurance that covers it will have access and those who do not will not have access.

“I am very excited, but I also wonder what the ramifications are,” continued Muzik.

“My biggest concern is how will those who have the greatest risk and need get access to the medication?"

Resources

If you or someone you’re with is having a life-threatening psychiatric emergency, please call 911.

For mental health crises and urgent concerns, dial 988 for the National Suicide and Crisis Lifeline.


More Articles About: Gynecology obstetrics and gynecology Postpartum Depression Adult Psychiatric Treatment Mental Health Mental Health Assessment Women's Health
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Michigan Medicine Presents... on dark blue background with two lights shining on the words
Michigan Medicine Presents
Episode 3: Medication, Relationships, and Caretaking
Like many other mental health conditions, bipolar disorder is still quite stigmatized in our society. Stigma can play a significant role in how people living with bipolar disorder receive treatment and care, their education and careers, and many other aspects of daily life. For this episode, we’ll be tackling topics like medications, relationships, the workplace, and supporting a loved one. We’ll be hearing from Dr. Sagar Parikh, a psychiatrist in the Michigan Medicine Bipolar Disorder Clinic and professor of psychiatry and of health policy and management in the School of Public Health at UofM, and Michelle Yang, writer, activist, marketing project manager, and research participant with the Heinz C. Prechter Bipolar Research Program.
Michigan Medicine Presents... on dark blue background with two lights shining on the words
Michigan Medicine Presents
Episode 1: The Science of Bipolar Disorder
Bipolar disorder is more than just mood swings. It’s a journey marked by intense highs of mania and debilitating lows of depression. But within this condition exist millions of people who live unique lives. Today, we're going to talk to three clinical and research experts from the Heinz C. Prechter Bipolar Research Program at Michigan Medicine to learn more about the science of bipolar disorder—diagnostics, genetics, and decision-making. We'll be hearing from Dr. Melvin McInnis, director of the Prechter Program, Dr. Paul Jenkins, associate professor of pharmacology and associate director of the Prechter Program, and Dr. Chandra Sripada, professor of psychiatry and philosophy.
Michigan Medicine Presents... on dark blue background with two lights shining on the words
Michigan Medicine Presents
Episode 2: Exploring the Meaning of Wellness
Research into conditions like bipolar disorder cannot happen without the participation of hundreds of people who sign up for research studies and programs like the Heinz C. Prechter Bipolar Research Program. In this episode, we’ll unpack wellness—how we define and measure it healthcare and research settings. We’re joined by Dr. Alexandra Vinson, assistant professor of Learning Health Sciences and co-lead of the Prechter Bipolar Disorder Learning Community. Stephanie Prechter, artist, philanthropist, a bipolar disorder research participant with lived experience and board member of the Prechter Program, and Dr. Sarah Sperry, director of the Emotion and Temporal Dynamics Lab and associate director of the Prechter Program.
Smiling photo of Jill Martin. She is standing in a white space wearing a dark plush coat, jeans, and sneakers.
Philanthropy News
TODAY show star and breast cancer survivor helps raise support for women’s health
TODAY show star Jill Martin aims to help improve health care for all women through the Women's Health Luncheon.
The Fundamentals Podcast Hero Card Final 1800 x 1350
The Fundamentals
How Can We Achieve Health Equity?
In today's episode of The Fundamentals, we talk with Dr. John Ayanian, director of the U-M Institute for Healthcare Policy and Innovation. Dr. Ayanian's research explores underlying factors that contribute to persistent health disparities between minoritized groups and their white counterparts, as well as strategies for ending inequity in health care and improving overall health outcomes for everyone.
breastfeeding pump close up woman holding it close up
Health Lab
Study examines lactation in critically ill patients
University of Michigan research reveals that simple awareness from the hospital care team can help protect a breastfeeding relationship for patients in the ICU and their newborn baby.